Skip to main content
Article thumbnail
Location of Repository

Molecular cloning and functional studies of tenascin-C isoforms containing the fibronectin-type III repeat additional domain 1 (AD1)

By David Stephen Guttery


Tenascin-C is an extracellular matrix glycoprotein expressed at low levels in normal breast tissue and highly expressed in both the stroma and malignant cells of solid tumours. Multiple isoforms of TNC are generated by alternative splicing. The aim of this study was: 1) to investigate the expression of key high molecular weight (MW) TNC isoforms containing domains D, B/D, AD1 and AD2 in normal, benign and malignant breast and relate expression to histopathological features, 2) to investigate the functional significance of AD1 by molecular cloning and 2D invasion assays, 3) to perform differential gene expression analysis using GeneChip arrays and relate to expression of high MW TNC isoforms in MCF-7 cells. \ud AD1 and AD2 were detected in all TNC positive breast cell lines, normal and tumour breast tissues and isolated cells from normal breast tissue, with myoepithelial cells being the major source of AD1. In carcinomas, expression of high MW TNC was significantly associated with younger age (≤ 40 years; p = < 0.05 for all isoforms), negative ER (p = 0.011 for AD1 and 0.032 for AD1/AD2 respectively) and high grade (p = 0.017 and 0.019 respectively). Expression of total TNC, TNC-9/16 and TNC-14/16 was also associated with negative CK14 (p = 0.003 for all), and higher TNC-14/16 expression was associated with lobular carcinomas (p = 0.004). Molecular cloning of AD1 and transfection studies using the TNC-14/AD1/16 isoform significantly increased MCF-7 cell invasion to a level comparable to TNC-9/14/16 (p = < 0.001). Differential gene expression analysis showed that TNC-9/14/16 and TNC-14/AD1/16 significantly increased expression of interferon-inducible transmembrane protein 1 (IFITM1) and profilin-1 (PFN1) in transfected MCF-7 cells. However, quantitative RT-PCR analysis of tissue samples showed significant down-regulation of PFN1 in tumours, compared to normal breast (p = 0.02), which was significantly associated with high TNC-14/16 expression (p = 0.002). \ud In conclusion, high MW TNC isoforms including AD1 have been associated with more aggressive features of breast carcinomas and in-vitro with an invasive phenotype. Moreover, this study also identifies PFN1 as a novel gene target associated with tumours that express high levels of TNC-14/16

Publisher: University of Leicester
Year: 2009
OAI identifier:

Suggested articles


  1. (1992). 1H NMR assignment and secondary structure of the cell adhesion type III module of fibronectin.
  2. (2005). 257 |P a g e Improved tumor targeting by combined use of two antitenascin antibodies.
  3. A cDNA clone for cytotactin contains sequences similar to epidermal growth factor-like repeats and segments of fibronectin and fibrinogen.
  4. (1982). A cell line (HBL-100) established from human breast milk.
  5. (1993). A common nuclear signal transduction pathway activated by growth factor and cytokine receptors.
  6. (1989). A detailed structural model of cytotactin: protein homologies, alternative RNA splicing, and binding regions.
  7. (2002). A family of Rab27-binding proteins. Melanophilin links Rab27a and myosin Va function in melanosome transport.
  8. (2000). a g e
  9. (2005). a g e Arnes
  10. (1996). a g e Borsi
  11. (1996). a g e Carnemolla
  12. (1982). a g e Childs
  13. (1998). a g e Fukamauchi
  14. (1993). a g e Hollywood DP,
  15. (1992). a g e Kawakatsu
  16. (1995). a g e Lohi
  17. (2004). a g e Mercado
  18. (1998). a g e Moscoso
  19. (1993). a g e Pantaloni
  20. (1996). a g e Rebbeck
  21. (1998). a g e Stambolic
  22. (2002). a g e Thiery JP.
  23. (2003). a g e Tsunoda
  24. (1997). a g e Vargas-Roig
  25. (1999). a g e Zirbes
  26. (2002). A gene-expression signature as a predictor of survival in breast cancer.
  27. (2007). A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer.
  28. (2006). A modular real-time PCR concept for determining the quantity and quality of human nuclear and mitochondrial DNA. Forensic Science International:
  29. (1993). A novel model of a metastatic human breast tumour xenograft line.
  30. (1993). A novel tenascin type III repeat is part of a complex of tenascin mRNA alternative splices.
  31. (2008). A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost.
  32. (1992). A simple procedure for tenascin purification.
  33. (1984). A six-armed oligomer isolated from cell surface fibronectin preparations.
  34. (2003). A splicing mutation affecting expression of ataxia-telangiectasia and Rad3-related protein (ATR) results in Seckel syndrome.
  35. (2003). A tenascin-C aptamer identified by tumor cell SELEX: systematic evolution of ligands bby exponential enrichment.
  36. (1996). Abnormal behavior and neurotransmissions of tenascin gene knockout mouse.
  37. (1977). Actin polymerizability is influenced by profilin, a low molecular weight protein in non-muscle cells.
  38. (2006). Activated Leukocyte Cell Adhesion Molecule (ALCAM) is associated with suppression of breast cancer cells invasion.
  39. (2004). Activated leukocyte cell adhesion molecule in breast cancer: prognostic indicator.
  40. (2001). Activation of STAT proteins and growth control.
  41. (1992). Allele losses in the region 17q12-21 in familial breast and ovarian cancer involve the wild-type chromosome.
  42. (1992). Alteration of stromal protein and integrin expression in breast--a marker of premalignant change?
  43. (1992). Altered content and distribution of tenascin in colitis, colon adenoma, and colorectal carcinoma.
  44. (2004). Alternative splicing in the aggrecan G3 domain influences binding interactions with tenascin-C and other extracellular matrix proteins.
  45. (1992). Alternative splicing products of the tenascin gene distinguish rat liver fat 262 |P a g e storing cells from arterial smooth muscle cells and skin fibroblasts.
  46. (1999). Alternatively spliced tenascin-C mRNA isoforms in human fetal membranes.
  47. (1991). Amino acid sequence of mouse tenascin and differential expression of two tenascin isoforms during embryogenesis.
  48. (1993). Amphiregulin induces tyrosine 244 |P a g e
  49. (1988). Amphiregulin: a bifunctional growth-modulating glycoprotein produced by the phorbol 12-myristate 13-acetate-treated human breast adenocarcinoma cell line MCF-7.
  50. (2005). Amphiregulin: an early trigger of liver regeneration in mice.
  51. (2008). Amphiregulin: role in mammary gland development and breast cancer.
  52. Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining.
  53. (1995). Amplification of chromosome band 11q13 and a role for cyclin D1 in human breast cancer.
  54. (1989). An alternatively spliced region of the human hexabrachion contains a repeat of potential N-glycosylation sites.
  55. (1975). An atlas of subgross pathology of the human breast with special reference to possible precancerous lesions.
  56. (1998). An important role for BRCA1 in breast cancer progression is indicated by its loss in a large proportion of non-familial breast cancers.
  57. (1995). An overview of epithelio-mesenchymal transformation. Acta Anat
  58. (2006). Analysis of structure and function of tenascin-C.
  59. (1999). Antisense expression for amphiregulin suppresses tumorigenicity of a transformed human breast epithelial cell line.
  60. (2004). Application of locked nucleic acids to improve aptamer in vivo stability and targeting function.
  61. (2006). Applications of the luminol chemiluminescent reaction in analytical chemistry.
  62. (1991). Assignment of the gene for human tenascin to the region q32-q34 of chromosome 9.
  63. (2008). Association of an extracellular matrix gene cluster with breast cancer prognosis and endocrine therapy response.
  64. (1999). Association of in vitro invasiveness and gene expression of estrogen receptor, progesterone receptor, pS2 and plasminogen activator inhibitor-1 in human breast cancer cell lines.
  65. (1992). Association of increased basement membrane invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines.
  66. (1987). Asymmetric expression in somites of cytotactin and its proteoglycan ligand is correlated with neural crest cell distribution.
  67. (2003). ATM, ATR and DNA-PK: initiators of the cellular genotoxic responses.
  68. (2009). ATR Mutation in Endometrioid Endometrial Cancer Is Associated With Poor Clinical Outcomes. J Clin Oncol (E-publication ahead of print).
  69. (2007). B5. iNOS expression is associated with basallike breast cancer phenotype and predicts poor survival in ERneg breast cancer. Nitric Oxide 17, Supplement 1:17.
  70. (2002). Balloon catheterization induces arterial expression of new Tenascin-C isoform.
  71. (2008). Basal cytokeratins in breast tumours among BRCA1, BRCA2 and mutation-negative breast cancer families. Breast Cancer Res 10:R17.
  72. (1996). Basal layer of epithelium expresses tenascin mRNA during healing of incisional skin wounds.
  73. (2008). Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype.
  74. (2008). Basal-like breast cancer: a critical review.
  75. (1996). Bergmann glial development in the mouse cerebellum as revealed by tenascin expression. Anat Embryol (Berl)
  76. (2005). beta-Catenin regulates the expression of tenascin-C in human colorectal tumors.
  77. (2000). Beta-catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression.
  78. (2003). Betacellulin and amphiregulin induce upregulation of cyclin D1 and DNA synthesis activity through differential signaling pathways in vascular smooth muscle cells.
  79. (1997). Biodistribution of 111In-labelled SCN-bz-DTPA-BC-2 MAb following loco-regional injection into glioblastomas.
  80. (1998). Biologic Markers in Breast Cancer: An Update.
  81. (1998). BRCA-associated breast cancer in young women.
  82. (2006). BRCA1 interacts with poly(A)-binding protein: implication of BRCA1 in translation regulation.
  83. (1994). BRCA1 mutations in primary breast and ovarian carcinomas.
  84. (1996). BRCA2 mutations in primary breast and ovarian cancers.
  85. (2003). Breast and ovarian cancer.
  86. (2003). Breast cancer classification and prognosis based on gene expression profiles from a population-based study.
  87. (2005). Breast cancer metastasis: markers and models.
  88. (1996). Breast carcinomas occurring in young women (< 35 years) are different.
  89. (2001). CALEB binds via its acidic stretch to the fibrinogen-like domain of tenascin-C or tenascin-R and its expression is dynamically regulated after optic nerve lesion.
  90. (1994). Can tenascin be redundant in cancer development?
  91. (1989). Cancerous versus noncancerous breasts. A comparative morphological analysis of the entire glandular tree of the breast. Virchows Arch A Pathol Anat Histopathol
  92. (2006). Canonical WNT signaling pathway and human AREG.
  93. (1999). CDK inhibitors: positive and negative regulators of G1-phase progression.
  94. (2000). Cell death-associated translocation of plasma membrane components induced by CTL.
  95. (1993). Cell- and heparin-binding domains of the hexabrachion arm identified by tenascin expression proteins.
  96. (2005). Changes in cytoskeletal protein composition indicative of an epithelial-mesenchymal transition in human micrometastatic and primary breast carcinoma cells.
  97. (2002). Changes in tenascin-C isoform expression in invasive and preinvasive breast disease.
  98. (1991). Characterization of a newt tenascin cDNA and localization of tenascin mRNA during newt limb regeneration by in situ hybridization.
  99. (1986). Characterization of breast carcinomas by two monoclonal antibodies distinguishing myoepithelial from luminal epithelial cells.
  100. (1986). Characterization of estrogen responsive transforming activity in human breast cancer cell lines.
  101. (1992). Characterization of multiple ahdesive and counteradhesive domains in the extracellular matrix protein cytotactin.
  102. (1991). Characterization of tenascin secreted by human melanoma cells.
  103. (1990). Chromosomal localization of the human hexabrachion (tenascin) gene and evidence for recent reduplication within the gene.
  104. (2006). Circulating level of large splice variants of tenascin-C is a marker of piecemeal necrosis activity in patients with chronic hepatitis C. Liver Int
  105. (2006). Circulating MMP2 and MMP9 in breast cancer -- potential role in 264 |P a g e classification of patients into low risk, high risk, benign disease and breast cancer categories.
  106. (2004). Clinical aspects of estrogen and progesterone receptors.
  107. (2008). Clinical experience with alphaparticle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6.
  108. (2002). Clinical impact and functional aspects of tenascin-C expression during glioma progression.
  109. (2006). Clinicians‟ guide to microarrays. Surg Oncol
  110. (1994). CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice.
  111. (1997). Co-expression of tenascin and fibronectin in epithelial and stromal cells of benign lesions and ductal carcinomas in the human breast.
  112. (2001). Co-expression of tenascin-C and vimentin in human breast cancer cells indicates phenotypic transdifferentiation during tumour progression: correlation with histopathological parameters, hormone receptors, and oncoproteins.
  113. (2004). Co-stimulation of human breast cancer cells with transforming growth factor-beta and tenascin-C enhances matrix metalloproteinase-9 expression and cancer cell invasion.
  114. (2005). Coding SNP in tenascin-C Fn-III-D domain associates with adult asthma.
  115. (1996). Combined analysis of expression of c-erbB-2, Ki-67 antigen, and tenascin provides a better prognostic indicator of carcinoma of the papilla of Vater.
  116. (2008). Combined lysophosphatidic acid/platelet-derived growth factor signaling triggers glioma cell migration in a tenascin-C microenvironment.
  117. (1991). Comparative analysis of the expression of the extracellular matrix protein tenascin in normal human fetal, adult and tumor tissues.
  118. (1991). Complete primary structure of porcine tenascin. Detection of tenascin transcripts in adult submaxillary glands.
  119. (1983). Complex cytokeratin polypeptide patterns observed in certain human carcinomas.
  120. (1995). Consistent loss of the wildtype allele in breast cancers from a family linked to the BRCA2 gene on chromosome 13q12–13.
  121. (1978). Control of hormone release during lactation.
  122. (2004). Coregulation of fibronectin signaling and matrix contraction by tenascin-C and syndecan-4.
  123. (1999). Corneal wound healing in tenascin knockout mouse.
  124. (1995). Cured of breast cancer?
  125. (1995). Cyclin D1 (PRAD1) protein expression in breast cancer: approximately one-third of infiltrating mammary carcinomas show overexpression of the cyclin D1 oncogene.
  126. (1996). Cyclin D1 and prognosis in human breast cancer.
  127. (1996). Cyclin D1 triggers autonomous growth of breast cancer cells by governing cell cycle exit.
  128. (2007). Cytokeratin KRT8/18 expression differentiates distinct subtypes of 270 |P a g e grade 3 invasive ductal carcinoma of the breast.
  129. (2001). Cytokeratins as markers of follicular differentiation: an immunohistochemical study of trichoblastoma and basal cell carcinoma.
  130. (1983). Cytokeratins of normal epithelia and some neoplasms of the female genital tract.
  131. (1991). D11S287, a putative oncogene on chromosome 11q13, is amplified and expressed in squamous cell and mammary carcinomas and linked to BCL-1. Oncogene
  132. (1997). Defective TNFalpha-induced apoptosis in STAT1-null cells due to low constitutive levels of caspases.
  133. (2004). DEGA/AMIGO-2, a leucine-rich repeat family member, differentially expressed in human gastric adenocarcinoma: effects on ploidy, chromosomal stability, cell adhesion/migration and tumorigenicity.
  134. Degradation of tenascin-C and activity of matrix metalloproteinase-2 are associated with tumor recurrence in early stage non-small cell lung cancer.
  135. (1998). Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice.
  136. (2005). Design, construction, and characterization of a large synthetic antibody phage display library.
  137. (1999). Detection of tenascin-C isoforms in colorectal mucosa, ulcerative colitis, carcinomas and liver metastases.
  138. Different proliferative activity of the glandular and myoepithelial lineages in benign proliferative and early malignant breast diseases.
  139. (1990). Differential distribution of tenascin in the normal, hyperplastic, and neoplastic breast. Lab Invest 63:798-806.
  140. (1994). Differential effects of cytotactin tenascin fusion proteins on intracellular pH and cell morphology.
  141. (1993). Differential expression of extracellular matrix proteins and integrins in hepatocellular carcinoma and chronic liver disease.
  142. (1995). Differential expression of oestrogen regulated genes in breast cancer.
  143. (2006). Differential expression of tenascin-C splicing domains in urothelial carcinomas of the urinary bladder.
  144. (1991). Differential response of the human 6-16 and 9-27 genes to alpha and gamma interferons.
  145. (1994). Differentiation state and invasiveness of human breast cancer cell lines.
  146. (1992). DiI as a marker for cellular transplantation into solid organs.
  147. (2006). Discovery and development of anticancer aptamers.
  148. (2004). Dissecting the metastatic cascade.
  149. (2006). Dissection of signaling pathways in fourteen breast cancer cell lines using reverse-phase protein lysate microarray.
  150. (1989). Distinctive traits of normal and tumor-derived human mammary epithelial cells expressed in a medium that supports long-term growth of both cell types.
  151. (1982). Distribution of myoepithelial cells and basement membrane proteins in the normal breast and in benign and malignant breast diseases.
  152. (1982). Distribution of myoepithelial cells and basement membrane proteins in the resting, pregnant, lactating, and involuting rat mammary gland.
  153. (1993). Distribution of tenascin in normal cycling human ovary. Hum Reprod 8:2015-2018.
  154. (1995). Distribution of the mammalian Stat gene family in mouse chromosomes.
  155. (1997). Distribution pattern of tenascin-C in normal and neoplastic mesenchymal tissues.
  156. (2001). DNA-PK, ATM and ATR as sensors of DNA damage: variations on a theme?
  157. (2008). Do 'basal-like' breast cancers really exist? Nat Rev Cancer:1-6.
  158. (2008). Does estrogen receptor negative/progesterone receptor positive breast carcinoma exist? J Clin Oncol 26:335-336; author reply 336-338.
  159. (2005). Dosimetry and radiographic analysis of 131I-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas.
  160. (2004). Down-regulated expression of cytokeratin 18 promotes progression of human breast cancer.
  161. (2000). Ductal carcinoma in situ (DCIS) of the breast: evolving perspectives.
  162. (2001). E-cadherin as a prognostic indicator in primary breast cancer.
  163. (2006). Ecadherin transcriptional downregulation by promoter methylation but not mutation is related to epithelial-to-mesenchymal transition in breast cancer cell lines.
  164. (1988). Effect of medroxyprogesterone acetate on proliferation and cell cycle kinetics of human mammary carcinoma cells.
  165. (2001). Effect of progesterone on the invasive properties and tumor growth of progesterone receptor-transfected breast cancer cells MDA-MB-231.
  166. (1997). Effects of cholecystokinin-B receptor antagonist on dopamine system in tenascin mutant mice.
  167. (2006). Effects of young age at presentation on survival in breast cancer.
  168. (2007). EGFR and Src are involved in indole-3-carbinol-induced death and cell cycle arrest of human breast cancer cells.
  169. (1979). Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.
  170. (1996). Elevated keratin 18 protein expression indicates a favorable prognosis in patients with breast cancer.
  171. (1993). Endothelial cell attachment and spreading on human tenascin is mediated by alpha 2 beta 1 and alpha v beta 3 integrins.
  172. (1993). Endothelial cells adhere to the RGD domain and the fibrinogen-like terminal knob of tenascin.
  173. (1999). Enforced CD19 expression leads to growth inhibition and reduced tumorigenicity.
  174. (2004). Enhanced tenascin-C expression and matrix deposition during Ras/TGF-beta-induced progression of mammary tumor cells.
  175. (2001). Epidermal growth factor (EGF)-like repeats of human tenascin-C as ligands for EGF receptor.
  176. epidermal growth factor receptor.
  177. (1996). Epidermal growth factor-related peptides activate distinct subsets of ErbB receptors and differ in their biological activities.
  178. (1994). Epithelial cells are an important source of tenascin in normal and malignant human breast tissue.
  179. (1985). Epithelial HBL-100 cell line derived from milk of an apparently healthy woman harbours SV40 genetic information.
  180. (1988). Epithelial induction of stromal tenascin in the mouse mammary gland: from embryogenesis to carcinogenesis.
  181. (1987). Epithelial-mesenchymal interactions in the developing kidney lead to expression of tenascin in the mesenchyme.
  182. (1979). Establishment and characterization of a cell line of human breast carcinoma origin.
  183. (1995). Estrogen and phorbol esters regulate amphiregulin expression by two separate mechanisms in human breast cancer cell lines.
  184. (1977). Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer.
  185. Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type.
  186. (2005). Estrogen receptor-negative breast carcinomas: a review of morphology and immunophenotypical analysis.
  187. (2007). Estrogen regulation of mammary gland development and breast cancer: amphiregulin takes center stage. Breast Cancer Res 9:304.
  188. (1999). Evidence for combinatorial variability of tenascin-C isoforms and developmental regulation in the mouse central nervous system.
  189. (2007). Expression analysis and RNA localization of PAIRBP1 (SERBP1) in epithelial ovarian cancer: association with tumor progression.
  190. (1993). Expression and amplification of cyclin genes in human breast cancer.
  191. (1998). Expression and degeneration of tenascin-C in human lung cancers.
  192. (1995). Expression and ligand binding of alpha 2 beta 1 integrin on breast carcinoma cells.
  193. (1990). Expression and production of tenascin in benign and malignant lesions of melanocyte lineage.
  194. (1996). Expression of adhesion molecules in endemic and epidemic Kaposi's sarcoma.
  195. (1988). Expression of basal and luminal epitheliumspecific keratins in normal, benign, and malignant breast tissue.
  196. (1992). Expression of different tenascin isoforms in normal, hyperplastic and neoplastic human breast tissues.
  197. (2007). Expression of large tenascin-C splice variants by hepatic stellate cells/myofibroblasts in chronic hepatitis C.
  198. (2004). Expression of luminal and basal cytokeratins in human breast carcinoma.
  199. (1999). Expression of tenascin in human cervical cancer--association of tenascin expression with clinicopathological parameters.
  200. (1993). Expression of tenascin in human gliomas: its relation to histological malignancy, tumor dedifferentiation and angiogenesis.
  201. (1996). Expression of tenascin is related to histologic malignancy and angiogenesis in b-cell non-Hodgkin's lymphomas.
  202. (1997). Expression of tenascin-C by human endometrial adenocarcinoma and stroma cells: heterogeneity of splice variants and induction by TGF-beta.
  203. (1997). Expression of tenascin-C in bones responding to mechanical load.
  204. (1998). Expression of tenascin-C in intraductal carcinoma of human breast: relationship to invasion.
  205. (2002). Expression of tenascin-C long isoforms is induced in the hypothalamus by FGF-1.
  206. (1996). Expression of the extracellular matrix protein tenascin in malignant and benign ovarian tumours.
  207. (2008). Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome.
  208. (2001). Female patients with breast carcinoma age 30 years and younger have a poor prognosis: the M.D. Anderson Cancer Center experience.
  209. (2009). FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).
  210. (1984). Fibrinogen and fibrin.
  211. (2000). Fibroblast growth factors, their receptors and signaling.
  212. (2001). Fibroblast growth factors.
  213. (2006). Fibroblasts in cancer.
  214. (1996). Fibrolamellar carcinoma of the liver: composition of the extracellular matrix and expression of cell-matrix and cellcell adhesion molecules.
  215. (1995). Fibronectin and integrins in invasion and metastasis.
  216. Focal adhesion integrity is downregulated by the alternatively spliced domain of human tenascin.
  217. (1985). Focal contacts of normal and RSV-transformed quail cells. Hypothesis of the transformation-induced deficient maturation of focal contacts.
  218. (2003). Folding-unfolding of FN-III domains in tenascin: an elastically coupled two-state system.
  219. (1995). Frequent alterations in E-cadherin and alpha- and beta-catenin expression in human breast cancer cell lines.
  220. (1988). Functional mapping of cytotactin: proteolytic fragments active in cell-substrate adhesion.
  221. (2007). GATA-6 is a novel transcriptional repressor of the human Tenascin-C gene expression in fibroblasts. Biochim Biophys Acta.
  222. (2001). Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.
  223. (2007). Gene expression profiling of breast, prostate, and glioma cells following single versus fractionated doses of radiation.
  224. (2002). Gene expression profiling predicts clinical outcome of breast cancer.
  225. (2005). Geneexpression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. The Lancet 365:671–679.
  226. (2007). Genome-wide association study identifies novel breast cancer susceptibility loci.
  227. (2000). Glioma-associated antigen expression in oligodendroglial neoplasms.
  228. (2005). Global cancer statistics,
  229. (1998). Heat shock protein expression and drug resistance in breast cancer patients treated with induction chemotherapy.
  230. (1987). Hexabrachion proteins in embryonic chicken tissues and human tumors.
  231. (1992). Histological grade of breast cancer in younger women.
  232. (1990). Homology of a domain of the growth hormone/prolactin receptor family with type III modules of fibronectin.
  233. (2003). Host microenvironment in breast cancer development: extracellular matrix-stromal cell contribution to neoplastic phenotype of epithelial cells in the breast.
  234. (1986). How is blood vessel growth regulated in normal and neoplastic tissue?
  235. (1993). Human amnion epithelial cells assemble tenascins and three fibronectin isoforms in the extracellular matrix.
  236. (1987). Human breast cancer: correlation of relapse and survival with amplification of the HER-2 ⁄ neu oncogene.
  237. (1983). Human glioma-mesenchymal extracellular matrix antigen defined by monoclonal antibody.
  238. (2006). Human monoclonal antibodies to domain C of tenascin-C selectively target solid tumors in vivo. Protein Eng Des Sel
  239. (1995). Human tenascin gene. Structure of the 5'-region, identification, and characterization of the transcription regulatory sequences.
  240. (1997). Human tenascin-C: identification of a novel type III repeat in oral cancer and of novel splice variants in normal, malignant and reactive oral mucosae.
  241. (1991). Human tenascin: primary structure, pre-mRNA splicing patterns and localization of the epitopes recognized by two monoclonal antibodies.
  242. (1990). Identification and characterization of the promoter for the cytotactin gene.
  243. (2004). Identification and kinetics analysis of a novel heparin-binding site (KEDK) in human tenascin-C.
  244. (1991). Identification of a cDNA clone specific for the oligodendrocyte-derived repulsive extracellular matrix molecule J1-160/180.
  245. (1999). Identification of a glioblastomaassociated tenascin-C isoform by a high affinity recombinant antibody.
  246. (2001). Identification of a neurite outgrowthpromoting motif within the alternatively spliced region of human tenascin-C.
  247. (2006). Identification of the IFITM family as a new molecular marker in human colorectal tumors.
  248. (2007). IFITM1 plays an essential role in the antiproliferative action of interferon-gamma.
  249. (1996). IL-4 upregulates tenascin synthesis in scleroderma and healthy skin fibroblasts.
  250. Immunohistochemical analysis of cytokeratin #8 as a prognostic factor in invasive breast carcinoma.
  251. (2002). Immunohistochemical expression of extracellular matrix components tenascin, fibronectin, collagen type IV and laminin in breast cancer: their prognostic value and role in tumour invasion and progression.
  252. (1995). Immunohistochemical expression of tenascin in normal stomach tissue, gastric carcinomas and gastric carcinoma in lymph nodes.
  253. (1999). Immunohistochemical localisation of tenascin in invasive ductal carcinoma of the breast.
  254. (2000). Immunohistochemical markers for intracranial ependymoma recurrence. An analysis of 88 cases.
  255. (1993). Immunohistochemical staining of tenascin in Warthin's tumor and in oncocytoma. Oral Surg Oral Med Oral Pathol 76:325-329.
  256. (2001). Improving the efficacy of antibody-based cancer therapies Nat Rev Cancer 1:118–129.
  257. (2001). Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families.
  258. (1993). Induction of tenascin in cancer cells by interactions with embryonic mesenchyme mediated by a diffusible factor.
  259. (1988). Induction of tenascin in healing wounds.
  260. (1996). Influence of interleukin 1 beta on tenascin distribution in human normal and osteoarthritic cartilage: a quantitative immunohistochemical study.
  261. (2004). Integrin signalling during tumour progression.
  262. (1998). Interactions among delta, serrate and fringe modulate notch activity during Drosophila wing development.
  263. (2001). Interference of tenascin-C with syndecan-4 binding to fibronectin blocks cell adhesion and stimulates tumor cell proliferation.
  264. (1991). Intersection of the complement and immune systems: a signal transduction complex of the B lymphocyte-containing complement receptor type 2 and CD19.
  265. (1979). Invasive lobular carcinoma of the breast: incidence and variants.
  266. (2007). Isogenic normal basal and luminal mammary epithelial isolated by a novel method show a differential response to ionizing radiation.
  267. (1990). Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10.
  268. (1989). Keratin expression in human mammary epithelial cells cultured from normal and malignant tissue: relation to in vivo phenotypes and influence of medium.
  269. (2008). Lobular carcinoma in situ.
  270. (1990). Localization during development of alternatively spliced forms of cytotactin mRNA by in situ hybridization.
  271. (1999). Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas.
  272. (1993). Localization of tenascin in uterine sarcomas and partially transformed endometrial stromal cells.
  273. (2006). Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer.
  274. (1978). Long-term human breast carcinoma cell lines of metastatic origin: preliminary characterization.
  275. (1994). Loss of heterozygosity in familial tumors from three BRCA1-linked kindreds.
  276. (2005). Lysyl oxidase regulates breast cancer cell migration and adhesion through a hydrogen peroxide-mediated mechanism.
  277. (1995). Mammary epithelial cell differentiation in vitro is regulated by an interplay of EGF action and tenascinC downregulation.
  278. (1994). Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice.
  279. (2001). Matrix metalloproteinase-2 is associated with tenascin-C in calcific aortic stenosis.
  280. (1998). Mechanism of cyclin D1 (CCND1, PRAD1) overexpression in human cancer cells: analysis of allele-specific expression.
  281. Mechanisms of inactivation of E-cadherin in breast cancer cell lines.
  282. (2006). Metastasis: a question of life or death.
  283. (1980). Metastatic potential correlates with enzymatic degradation of basement membrane collagen.
  284. (1997). Methylation of the BRCA1 gene in sporadic breast cancer.
  285. (1992). Mice develop normally without tenascin.
  286. (2001). Minimum Information About a Microarray Experiment (MIAME)-toward standards for microarray data.
  287. (2008). Modulation of cell cycles and apoptosis by apicidin in estrogen receptor (ER)-positive and-negative human breast cancer cells.
  288. (1991). Molecular analysis of a human interferon-inducible gene family.
  289. (2008). Molecular analysis of Bcl-2 and cyclin D1 expression in differentially expressing estrogen receptor breast cancer MCF7, T47D and MDA-MB-468 cell lines treated with adriamycin.
  290. (1993). Molecular aspects of tumor cell invasion and metastasis.
  291. (2008). Molecular basis of metastasis.
  292. (2005). Molecular classification and molecular forecasting of breast cancer: ready for clinical application?
  293. (2005). Molecular evolution of breast cancer.
  294. (1988). Molecular forms, binding functions, and developmental expression patterns of cytotactin and cytotactin-binding proteoglycan, an interactive pair of extracellular matrix molecules.
  295. (2007). Molecular mechanism of tenascin-C action on matrix metalloproteinase-1 invasive potential. Exp Biol Med
  296. (2000). Molecular portraits of human breast tumours.
  297. (2005). Molecular requirements for epithelialmesenchymal transition during tumor progression.
  298. (2003). Molecular signature associated with bone marrow micrometastasis in human breast cancer.
  299. (1997). Molecules in focus: tenascin-C.
  300. (1991). Morphological expression of cell transformation induced by c-Ha-ras oncogene in human breast epithelial cells.
  301. (1997). Multicellular origin of tenascin in skin tumors--an in situ hybridization study.
  302. (1982). Multicentricity and bilaterality in invasive breast carcinoma.
  303. (1993). Multiple integrins mediate cell attachment to cytotactin/tenascin.
  304. (2004). Murine tenascin-W: a novel mammalian tenascin expressed in kidney and at sites of bone and smooth muscle development.
  305. (1991). Murine tenascin: cDNA cloning, structure and temporal expression of isoforms.
  306. (2001). Mutations in Mlph, encoding a member of the Rab effector 252 |P a g e family, cause the melanosome transport defects observed in leaden mice.
  307. (1991). Mutations in the p53 gene in primary human breast cancers.
  308. (2004). Myoepithelial markers are expressed in at least 29% of oestrogen receptor negative invasive breast carcinoma.
  309. (1984). Neural cell adhesion molecules and myelin-associated glycoprotein share a common carbohydrate moiety recognized by monoclonal antibodies L2 and HNK-1.
  310. (2007). Neural Stem/Progenitor Cells Express 20 Tenascin C Isoforms That Are Differentially Regulated by Pax6.
  311. (2005). Neurite guidance by the FnC repeat of human tenascin-C: neurite attraction vs. neurite retention.
  312. (2001). Neurocan: a brain chondroitin sulfate proteoglycan.
  313. (1992). Neuronal cell adhesion molecule contactin/F11 binds to tenascin via its immunoglobulin-like domains.
  314. (1991). New aspects of stroma-parenchyma relations in mammary gland differentiation.
  315. (2002). New functions for the matrix metalloproteinases in cancer progression.
  316. (2005). Novel role for amphiregulin in protection from liver injury.
  317. (1998). Novel splice variants of human tenascin-C mRNA identified in normal and bullous keratopathy corneas.
  318. (1994). Novel tenascin variants with a distinctive pattern of expression in the avian embryo.
  319. (2002). Occurrence of a glioblastoma-associated tenascin-C isoform in cerebral cavernomas and neighboring vessels. Neurosurgery 50:838-842; discussion 842.
  320. (1992). Oestrogen receptor, epidermal growth factor receptor and oncoprotein expression in non-involved tissue of cancerous breasts.
  321. (1994). Oestrogen-regulated genes in breast cancer: association of pLIV1 with lymph node involvement.
  322. (1996). Oncogenic regulation and function of keratins 8 and 18. Cancer Metastasis Rev
  323. (2009). Over-expression of metallothionein predicts chemoresistance in breast cancer.
  324. (2008). Overexpression of beta2-microglobulin is associated with poor survival in patients with oral cavity squamous cell carcinoma and contributes to oral cancer cell migration and invasion.
  325. (2004). Overexpression of profilin reduces the migration of invasive breast cancer cells.
  326. P a g e Gorgoulis VG.
  327. (1999). P-cadherin expression in breast carcinoma indicates poor survival.
  328. (1997). Paradoxical behavioral response to apomorphine in tenascin-gene knockout mouse.
  329. (2008). Patho-biological aspects of basal-like breast cancer. Breast Cancer Res Treat.
  330. (2002). Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with longterm follow-up.
  331. (1985). Patterns of expression and organization of cytokeratin intermediate filaments.
  332. Phase II trial of murine (131) I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas.
  333. (2006). Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol
  334. (2005). Potential oncogenic action of tenascin-C in tumorigenesis.
  335. (2008). Predictive markers in breast cancer--the present.
  336. (1995). Predictive value of ER1D5 antibody immunostaining in breast cancer. A paraffin-based retrospective study of 257 cases.
  337. (1997). Preprotachykinin A and cholecystokinin mRNAs in tenascin-gene knockout mouse brain.
  338. (2003). Primary breast myoepithelial cells exert an invasion-suppressor effect on breast cancer cells via paracrine downregulation of MMP expression in fibroblasts and tumour cells.
  339. (2004). Production of recombinant human tenascin-C module containing a cell adhesion recognition motif of RGD.
  340. (1999). Profilin promotes barbed-end actin filament assembly without lowering the critical concentration.
  341. Profilin-1 is a negative regulator of mammary carcinoma aggressiveness.
  342. (2009). Profilin-1 overexpression upregulates PTEN and suppresses AKT activation in breast cancer cells.
  343. (1997). Profilins as regulators of actin dynamics.
  344. (2000). Progesterone induces focal adhesion in breast cancer cells MDA-MB-231 transfected with progesterone receptor complementary DNA.
  345. (2003). Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases.
  346. (1985). Prognosis of breast cancer patients after mastectomy and dissection of internal mammary nodes.
  347. (2008). Prognostic effect of estrogen receptor status across age in primary breast cancer.
  348. (2004). Prognostic molecular markers in early breast cancer.
  349. (1984). Prognostic significance of estrogen receptor status in breast cancer in relation to tumor stage, axillary node metastasis, and histopathologic grading.
  350. (2000). Prognostic significance of young age in breast cancer.
  351. (1997). Proliferating cell nuclear antigen and heat shock protein 70 immunolocalization in invasive ductal breast cancer not otherwise specified.
  352. (2000). Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors.
  353. (1982). Prospective study of a family cancer syndrome.
  354. (2005). Proteomic study reveals that proteins involved in metabolic and detoxification pathways are highly expressed in HER-2/neu-positive breast cancer.
  355. (2001). Quantitative analysis of BRCA1 and BRCA2 mRNA expression in sporadic breast carcinomas and its relationship with with clinicopathological characteristics.
  356. (1998). Quantitative in situ localization of tenascin-C alternatively spliced transcripts in the avian optic tectum.
  357. (2002). Quantitative reverse transcription-polymerase chain reaction measurement of HASH1 (ASCL1), a marker for small cell lung carcinomas with neuroendocrine features.
  358. (2006). Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.
  359. (1991). Rapid epithelialisation of fetal wounds is associated with the early deposition of tenascin.
  360. (1998). Reduced mRNA expression of neuropeptide Y in the limbic system of tenascin gene disrupted mouse brain.
  361. (1991). Reduced tenascin expression in colonic carcinoma with lymphogenous metastasis.
  362. (2001). Regulation of cell function by methionine oxidation and reduction.
  363. (1995). Regulation of EGF-induced tenascin-C by steroids in tenascin-C-non-producing human carcinoma cells.
  364. (2006). Regulation of vimentin by SIP1 in human epithelial breast tumor cells.
  365. (1994). Relationship of patient age to pathologic features of the tumor and prognosis for patients with stage I or II breast cancer.
  366. (2004). Relevance of breast cancer cell lines as models for breast tumours: an update.
  367. (2003). Repeated observation of breast tumor subtypes in independent gene expression data sets.
  368. (1991). Restrictin: a chick neural extracellular matrix protein involved in cell attachment co-purifies with the cell recognition molecule F11.
  369. (1999). Robbins Pathologic Basis of Disease.
  370. (2004). Roles and regulation of stat family transcription factors in human breast cancer.
  371. (2006). Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results.
  372. Selection of potentially metastatic subpopulations expressing c-erbB-2 from breast cancer tissue by use of an extravasation model.
  373. (2006). Silencing profilin-1 inhibits endothelial cell proliferation, migration and cord morphogenesis.
  374. (1986). Site-restricted expression of cytotactin during development of the chicken embryo.
  375. (1996). Skin wounds and severed nerves heal normally in mice lacking tenascinC.
  376. (1986). Specific enzymatic amplification of DNA in vitro: the polymerase chain reaction.
  377. (1975). Specific progesterone receptors in human breast cancer.
  378. (2001). Specific protection against breast cancers by cyclin D1 ablation.
  379. (2002). staging system for breast cancer.
  380. (2005). STAT1 signaling regulates tumor-associated macrophage-mediated T cell deletion.
  381. (2000). STATs in oncogenesis.
  382. (1993). Steady-state levels of different tenascin mRNAs in various normal human tissues.
  383. (1998). Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes.
  384. (1989). Stimulation of human neuronectin secretion by brain-derived growth factors.
  385. (1989). Stimulation of tenascin expression in mesenchyme by epithelial-mesenchymal interactions.
  386. (2007). Stromal cells associated with early invasive foci in human mammary ductal carcinoma in situ coexpress urokinase and urokinase receptor.
  387. (1991). Stromal regulation of epithelial function.
  388. (1989). Structure and function of human amphiregulin: a member of the epidermal growth factor family.
  389. (1993). Structure and mechanism of 70-kDa heat-shock-related proteins.
  390. (1992). Structure of a fibronectin type III domain from tenascin phased by MAD analysis of the selenomethionyl protein.
  391. (1991). Structure of the human hexabrachion (tenascin) gene.
  392. (1996). Suppression of apoptosis by basement membrane requires three-dimensional tissue organization and withdrawal from the cell cycle.
  393. Suppression of tumorigenicity in breast cancer cells by the microfilament protein profilin 1.
  394. (1999). Syndecan-4 signals cooperatively with integrins in a 261 |P a g e Rho-dependent manner in the assembly of focal adhesions and actin stress fibers.
  395. (2005). Synergistic tumoricidal effect between celecoxib and adenoviral-mediated delivery of mda-7 in human breast cancer cells.
  396. (1999). Synthesis and protein distribution of the unspliced large tenascin-C isoform in oral squamous cell carcinoma.
  397. (1996). Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease.
  398. (1996). Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway.
  399. (2006). Tenascin C and annexin II expression in the process of pancreatic carcinogenesis.
  400. (2004). Tenascin C and cathepsin d expression in adipocytic tumors: an immunohistochemical investigation of 43 cases.
  401. (1989). Tenascin distribution in basal cell carcinomas.
  402. (1995). Tenascin distribution in human brain tumours. Acta Neurochir
  403. (1990). Tenascin distribution in the 235 |P a g e
  404. Tenascin expression at the invasive front is associated with poor prognosis in intrahepatic cholangiocarcinoma.
  405. (1995). Tenascin expression in cancer cells and stroma of human breast cancer and its prognostic significance.
  406. (1996). Tenascin expression in cutaneous fibrohistiocytic tumors. Immunohistochemical investigation of 24 cases.
  407. (1992). Tenascin expression in human chronic liver disease and in hepatocellular carcinoma.
  408. (2002). Tenascin expression in normal, hyperplastic, and neoplastic endometrium.
  409. (2000). Tenascin expression in primary and recurrent breast carcinomas and the effect of tenascin on breast tumor cell cultures.
  410. (1990). Tenascin expression in the human endometrium and in endometrial adenocarcinomas.
  411. (1995). Tenascin in breast cancer development--is epithelial tenascin a marker for poor prognosis?
  412. (1996). Tenascin in human papillomavirus associated lesions of the uterine cervix.
  413. (1993). Tenascin in inflammatory conditions and neoplasms of the urinary bladder.
  414. (1991). Tenascin in normal, reactive, hyperplastic, and neoplastic tissues: biologic and pathologic implications.
  415. (2003). Tenascin in preinvasive lesions of the vulva and vulvar cancer.
  416. (1992). Tenascin in reactive lymph nodes and in malignant lymphomas.
  417. (1987). Tenascin is a stromal marker for epithelial malignancy in the mammary gland.
  418. (1994). Tenascin is induced at implantation sites in the mouse uterus and interferes with epithelial cell adhesion.
  419. (1995). Tenascin knockout mice: barrels, boundary molecules, and glial scars.
  420. (1989). Tenascin mediates cell attachment through an RGDdependent receptor.
  421. (1991). Tenascin Mr 220,000 isoform expression correlates with corneal cell migration.
  422. (1994). Tenascin mRNA isoforms in the developing mouse brain.
  423. (1993). Tenascin staining positivity and the survival of patients with invasive breast carcinoma.
  424. (2000). Tenascin-A marker for the malignant potential of preinvasive breast cancers.
  425. (2004). Tenascin-C and SF/HGF produced by myofibroblasts in vitro provide convergent pro-invasive signals to human colon cancer cells through RhoA and Rac.
  426. (2003). Tenascin-C blocks cell-cycle progression of anchorage-dependent fibroblasts on fibronectin through inhibition of syndecan-4.
  427. (1999). Tenascin-C contains domains that independently regulate neurite outgrowth and neurite guidance.
  428. (1998). Tenascin-C expression in invasion border of early breast cancer: a predictor of local and distant recurrence.
  429. (1998). Tenascin-C expression in prostatic intraepithelial neoplasia (PIN): a marker of progression?
  430. (1998). Tenascin-C hexabrachion assembly is a sequential two-step process initiated by coiled-coil alpha-helices.
  431. (2000). Tenascin-C in development and disease: gene regulation and cell function.
  432. (1995). Tenascin-C inhibits extracellular matrix-dependent gene expression in mammary epithelial cells. Localization of active regions using recombinant tenascin fragments.
  433. (1996). Tenascin-C inhibits oligodendrocyte precursor cell migration by both adhesion-dependent and adhesion-independent mechanisms.
  434. (2002). Tenascin-C modulates matrix contraction via focal adhesion kinase- and Rho-mediated signaling pathways.
  435. (1999). Tenascin-C modulates tumor stroma and monocyte/macrophage recruitment but not tumor growth or metastasis in a mouse strain with spontaneous mammary cancer.
  436. (1998). Tenascin-C promotes healing of Habu-snake venom-induced glomerulonephritis: studies in knockout congenic mice and in culture.
  437. (2004). Tenascin-C regulates angiogenesis in tumor through the regulation of vascular endothelial growth factor expression.
  438. (2001). Tenascin-C splice variant adhesive/anti-adhesive effects on chondrosarcoma cell attachment to fibronectin. Cell Struct Funct
  439. (2006). Tenascin-C stimulates glioma cell invasion through matrix metalloproteinase-12.
  440. (2000). Tenascin-C suppresses Rho activation.
  441. (2003). Tenascin-C upregulates matrix metalloproteinase-9 in breast cancer cells: direct and synergistic effects with transforming growth factor beta1.
  442. (2005). Tenascin-C, over expressed in lung cancer down regulates effector functions of tumor infiltrating lymphocytes.
  443. (2005). Tenascin-W is found in malignant mammary tumors, promotes alpha8 integrin-dependent motility and requires p38MAPK activity for BMP-2 and TNF-alpha induced expression in vitro.
  444. (1997). Tenascin-X deficiency is associated with Ehlers-Danlos syndrome.
  445. (2002). Tenascin-X deficiency mimics Ehlers-Danlos syndrome in mice through alteration of collagen deposition.
  446. (1996). Tenascin-X expression in tumor cells and fibroblasts: glucocorticoids as negative regulators in fibroblasts.
  447. (1993). Tenascin-X: a novel extracellular matrix protein encoded by the human XB gene overlapping P450c21B.
  448. (1996). Tenascin-Y: a 240 |P a g e Hay ED.
  449. (1996). Tenascin: a multifunctional extracellular matrix protein with a restricted distribution in development and disease.
  450. (1989). Tenascin: an extracellular matrix protein prominent in specialized embryonic tissues and tumors.
  451. Tenascin: cDNA cloning and induction by TGF-beta.
  452. (1996). Tenascin: growth and adhesion modulation--extracellular matrix degrading function: an in vitro study.
  453. (2006). TenascinC patterns and splice variants in actinic keratosis and cutaneous squamous cell carcinoma.
  454. (2002). TenascinC promotes neurite outgrowth of embryonic hippocampal neurons through the alternatively spliced fibronectin type III BD domains via activation of the cell adhesion molecule F3/contactin.
  455. (2003). Tenascins: regulation and putative functions Cleton-Jansen
  456. (1995). TGF-beta regulates expression of tenascin alternativesplicing isoforms in fetal rat lung.
  457. (2005). The &quot;portrait&quot; of hereditary breast cancer.
  458. (2001). The alternatively spliced domain TnFnIII A1A2 of the extracellular matrix protein tenascin-C suppresses 258 |P a g e activation-induced T lymphocyte proliferation and cytokine production.
  459. (1990). The amphiregulin gene encodes a novel epidermal growth factor-related protein with tumor-inhibitory activity.
  460. (1982). The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells.
  461. (1992). The CD19/CD21 signal transducing complex of human B lymphocytes includes the target of antiproliferative antibody-1 and Leu-13 molecules.
  462. (2008). The cell-cell adhesion molecule E-cadherin. Cell Mol Life Sci
  463. (1991). The complete cDNA sequence of human hexabrachion (Tenascin). A multidomain protein containing unique epidermal growth factor repeats.
  464. The distinctive nature of HER2-positive breast cancers.
  465. (1990). The distribution of immuno-reactive tenascin in the epithelial-mesenchymal junctional areas of benign and malignant squamous epithelia.
  466. (1996). The epidermal growth factor receptor couples transforming growth factoralpha, heparin-binding epidermal growth factor-like factor, and amphiregulin to Neu, ErbB-3, and ErbB-4.
  467. (1997). The fibrinogen-like globe of tenascin-C mediates its interactions with neurocan and phosphacan/protein-tyrosine phosphatasezeta/beta.
  468. (1994). The functional role of cytotactin/tenascin in morphogenesis: a modest proposal.
  469. (1997). The human myoepithelial cell is a natural tumor suppressor.
  470. (1991). The human placenta: a model for tenascin expression.
  471. (1994). The inherited component of cancer.
  472. (1994). The integrin alpha 9 beta 1 mediates cell attachment to a non-RGD site in the third fibronectin type III repeat of tenascin.
  473. (2005). The interferon-inducible 9-27 gene modulates the susceptibility to natural killer cells and the invasiveness of gastric cancer cells.
  474. (1997). The intermediate filaments and prognostically oriented morphological classification in ductal breast carcinoma.
  475. (2001). The interplay of matrix metalloproteinases, morphogens and growth factors is necessary for branching of mammary epithelial cells.
  476. (1985). The J1 glycoprotein--a novel nervous system cell adhesion molecule of the L2/HNK-1 family.
  477. (1992). The junction between cytokines and cell adhesions.
  478. (2003). The LZT proteins; the LIV-1 subfamily of zinc transporters.
  479. (2001). The mammary myoepithelial cell--Cinderella or ugly sister?
  480. (2001). The microenvironment of the tumour-host interface.
  481. (1996). The Molecular Biology of Tenascin: Structure, Splice Variants, and Regulation of Gene Expression.
  482. (1998). The molecular elasticity of the extracellular matrix protein tenascin.
  483. (2006). The molecular portraits of breast tumors are conserved across microarray platforms.
  484. (1997). The multiple roles of tumour stroma.
  485. (1997). The myoepithelial defense: a host defense against cancer.
  486. (2009). The oestrogen receptor-negative/progesterone receptorpositive breast tumour: a biological entity or a technical artefact?
  487. (1993). The p53-binding protein MDM2 gene is differentially expressed in human breast carcinoma.
  488. (1999). The parathyroid hormone-related protein (PTHrP) gene: use of downstream TATA promotor and PTHrP 1-139 coding pathways in primary breast cancers vary with the occurrence of bone metastasis.
  489. (1998). The peripheral nerve and the neuromuscular junction are affected in the tenascin-C-deficient mouse.
  490. (1985). The prevalence of carcinoma in situ in normal and cancer-associated breasts.
  491. (2008). The regulation of tenascin expression by tissue microenvironments. Biochim Biophys Acta.
  492. (1986). The relation between survival and age at diagnosis in breast cancer.
  493. (1995). The role of amphiregulin in breast cancer.
  494. (2003). The roles of Rab27 and its effectors in the regulated secretory pathways.
  495. (1991). The sequential expression of tenascin mRNA in epithelium and mesenchyme during feather morphogenesis.
  496. (1987). The solution structure of human epidermal growth factor.
  497. (2000). The tenascin family of ECM glycoproteins: structure, function, and regulation during embryonic development and tissue remodeling.
  498. (1999). The tenascin-C knockout revisited.
  499. (1993). The three faces of profilin.
  500. (1992). The three-dimensional structure of the first EGF-like module of human factor IX: comparison with EGF and TGF-alpha.
  501. (2008). The ubiquitin-like molecule interferon-stimulated gene 15 (ISG15) is a potential prognostic marker in human breast cancer. Breast Cancer Res 10:R58.
  502. (2004). Tissue repair and the dynamics of the extracellular matrix.
  503. (1999). Transcription factor activities and gene expression during mouse mammary gland involution.
  504. (1995). Transcriptional responses to polypeptide ligands: the JAK-STAT pathway.
  505. (1996). Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon alpha and interferon gamma.
  506. (1993). Tumor cell interactions with the extracellular matrix during invasion and metastasis.
  507. tumor localization of 131I-labeled anti-tenascin monoclonal antibody 81C6 in patients with gliomas and other intracranial malignancies.
  508. (1997). Tumor-related prognostic factors for breast cancer.
  509. (1998). Tumor-suppressor p53: implications for tumor development and prognosis.
  510. (2005). Tumour vascular targeting.
  511. (1989). Two contrary functions of tenascin: dissection of the active sites by recombinant tenascin fragments.
  512. (1996). Two distinct phases of apoptosis in mammary gland involution: proteinase-independent and -dependent pathways.
  513. (1977). Two syngeneic cell lines from human breast tissue: the aneuploid mammary epithelial (Hs578T) and the diploid myoepithelial (Hs578Bst) cell lines.
  514. (1997). Tyrosine hydroxylase activity and its mRNA level in dopaminergic neurons of tenascin gene knockout mouse.
  515. (2006). Upregulation of tenascin-C expression by IL-13 in human dermal fibroblasts via the phosphoinositide 3-kinase/Akt and the protein kinase C signaling pathways.
  516. (1988). Vimentin and p53 expression on epidermal growth factor receptor-positive, oestrogen receptornegative breast carcinomas.
  517. (1990). Vimentin expression appears to be associated with poor prognosis in node-negative ductal NOS breast carcinomas.
  518. (1990). Vimentin is preferentially expressed in high-grade ductal and medullary, but not in lobular breast carcinomas.
  519. (1989). Vimentin rather than keratin expression in some hormone-independent breast cancer cell lines and in oncogene-transformed mammary epithelial cells.
  520. (1990). What distinguishes tenascin from fibronectin?
  521. (2001). When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer.
  522. (2007). Wnt signaling pathway in invasive ductal carcinoma of the breast: relationship between beta-catenin, dishevelled and cyclin D1 expression.
  523. (1998). Zebrafish tenascin-W, a new member of the tenascin family.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.